Hospital Quironsalud Barcelona

The Instituto de Oncología de Barcelona includes a strong program in cardiovascular disease, evaluating new therapies to lower heart‑related events and improve blood pressure control.

• Atherosclerotic cardiovascular disease
• Heart failure
• Hypertension
• High cardiovascular risk
• Established cardiovascular disease

With more than 120 active trials and 59 investigators, Hospital Quironsalud Barcelona is advancing preventive and treatment strategies for heart conditions.

Research at the site targets digestive system diseases, focusing on innovative treatments for gastrointestinal cancers and related disorders.

• Colorectal cancer
• Gastric cancer
• Esophageal cancer
• Pancreatic ductal adenocarcinoma
• Non‑muscle invasive bladder cancer

Trials explore targeted agents, immunotherapies, and combination regimens to increase survival and quality of life for patients with digestive tract malignancies.

The centre conducts studies in hemic and lymphatic diseases, aiming to improve outcomes for blood‑related cancers and disorders.

• Diffuse large B‑cell lymphoma
• Follicular lymphoma
• Other hematologic malignancies
• Chronic lymphocytic leukemia (investigational)
• Myeloma (early‑phase studies)

By testing novel antibodies and cellular therapies, investigators seek to enhance remission rates and reduce treatment toxicity.

A dedicated effort focuses on immune system diseases, including autoimmune conditions and immune‑modulating cancer therapies.

• Rheumatoid arthritis
• Immune checkpoint inhibitor combinations
• Autoimmune adverse event management
• Inflammatory biomarkers research
• Immunotherapy safety profiling

The program evaluates how modulating immune pathways can both treat malignancies and alleviate autoimmune disease activity.

The primary focus of the institute is on neoplasms, conducting extensive trials across a wide spectrum of solid tumors.

• Breast cancer (including HER2‑positive, triple‑negative, HR+)
• Non‑small cell lung cancer
• Prostate cancer
• Ovarian cancer
• Bladder cancer
• Melanoma
• Head and neck squamous cell carcinoma
• Gastric and gastro‑oesophageal junction adenocarcinoma
• Pancreatic cancer
• Renal cell carcinoma

Trials range from early‑phase safety studies to late‑stage efficacy assessments, seeking better response rates, longer survival, and improved quality of life.

Studies in nutritional and metabolic diseases address metabolic syndrome, lipid disorders, and diabetes‑related complications.

• Hypertriglyceridemia (severe and moderate)
• Obesity
• Type 2 diabetes mellitus
• Chronic kidney disease with metabolic involvement
• Lipid metabolism modulation

By testing agents such as inclisiran, finerenone, and empagliflozin, investigators aim to reduce cardiovascular events and renal decline.

The site includes research on respiratory tract diseases, combining oncology and infectious disease approaches.

• Non‑small cell lung cancer
• Small cell lung cancer
• Respiratory syncytial virus infection
• Influenza immunisation
• Bronchial inflammation studies

Clinical trials evaluate novel immunotherapies, antiviral vaccines, and supportive care strategies to improve lung health.

Research in virus diseases focuses on prevention and treatment of viral infections affecting vulnerable populations.

• Influenza vaccination efficacy
• Respiratory syncytial virus (RSV) therapeutics
• Human metapneumovirus studies
• Virus‑associated cancer immunotherapy
• COVID‑19 follow‑up investigations (observational)

The program seeks to enhance immunity, reduce disease severity, and explore viral antigens as targets for cancer treatment.

Investigations of metabolism explore biochemical pathways that influence disease progression and treatment response.

• Lipid metabolism and atherosclerotic risk
• Albumin‑creatinine ratio in chronic kidney disease
• Metabolic profiling of tumor microenvironment
• Glucose homeostasis in diabetic patients
• Energy balance in cancer cachexia

By linking metabolic biomarkers to therapeutic outcomes, researchers aim to personalize interventions across multiple disease areas.

The institute also studies fundamental physiological processes that underlie health and disease.

• Cardiovascular homeostasis
• Immune system regulation
• Cellular signaling in tumor growth
• Renal filtration dynamics
• Respiratory gas exchange efficiency

Understanding these processes supports the development of therapies that restore normal function and improve patient outcomes.